Alpha 2.0

» Articles » PMID: 35175548

Remnants, LDL, and the Quantification of Lipoprotein-Associated Risk in Atherosclerotic Cardiovascular Disease

Overview

Overview

Journal Curr Atheroscler Rep

Publisher Springer

Specialty Cardiology & Vascular Diseases

Date 2022 Feb 17

PMID 35175548

Authors

Authors

Chris J Packard

Affiliations

Affiliations

Soon will be listed here.

Abstract

Purpose Of Review: Implementation of intensive LDL cholesterol (LDL-C) lowering strategies and recognition of the role of triglyceride-rich lipoproteins (TRL) in atherosclerosis has prompted re-evaluation of the suitability of current lipid profile measurements for future clinical practice.

Recent Findings: At low concentrations of LDL-C (< 1.8 mmol/l/70 mg/dl), the Friedewald equation yields estimates with substantial negative bias. New equations provide a more accurate means of calculating LDL-C. Recent reports indicate that the increase in risk per unit increment in TRL/remnant cholesterol may be greater than that of LDL-C. Hence, specific measurement of TRL/remnant cholesterol may be of importance in determining risk. Non-HDL cholesterol and plasma apolipoprotein B have been shown in discordancy analyses to identify individuals at high risk even when LDL-C is low. There is a need to adopt updated methods for determining LDL-C and to develop better biomarkers that more accurately reflect the abundance of TRL remnant particles.

Citing Articles

Beyond LDL cholesterol: remnant cholesterol is associated with cardiometabolic risk factors in children.

Torres-Costoso A, Martinez-Vizcaino V, Oliveira A, Sanchez-Lopez M, Rodriguez-Gutierrez E, Nunez de Arenas-Arroyo S BMC Med. 2025; 23(1):28.

PMID: 39838462 PMC: 11752687. DOI: 10.1186/s12916-025-03859-9.

Daily steps, cardiorespiratory fitness, and remnant cholesterol in schoolchildren: mediation effects for cardiovascular prevention.

Rodriguez-Gutierrez E, Martinez-Vizcaino V, Bizzozero-Peroni B, Diaz-Goni V, Martinez-Garcia I, Sequi-Dominguez I Pediatr Res. 2024; .

PMID: 39695264 DOI: 10.1038/s41390-024-03779-z.

Impact of Remnant Cholesterol on Cardiovascular Risk in Diabetes.

Elias-Lopez D, Wadstrom B, Vedel-Krogh S, Kobylecki C, Nordestgaard B Curr Diab Rep. 2024; 24(12):290-300.

PMID: 39356419 DOI: 10.1007/s11892-024-01555-1.

It is time to address the contribution of cholesterol in all apoB-containing lipoproteins to atherosclerotic cardiovascular disease.

Toth P, Banach M Eur Heart J Open. 2024; 4(4):oeae057.

PMID: 39165648 PMC: 11335015. DOI: 10.1093/ehjopen/oeae057.

A significant presence in atherosclerotic cardiovascular disease: Remnant cholesterol: A review.

Wang L, Zhang Q, Wu Z, Huang X Medicine (Baltimore). 2024; 103(27):e38754.

PMID: 38968507 PMC: 11224847. DOI: 10.1097/MD.0000000000038754.

References

1.

Vehtari A, Makinen V, Soininen P, Ingman P, Makela S, Savolainen M . A novel Bayesian approach to quantify clinical variables and to determine their spectroscopic counterparts in 1H NMR metabonomic data. BMC Bioinformatics. 2007; 8 Suppl 2:S8. PMC: 1892077. DOI: 10.1186/1471-2105-8-S2-S8. View

2.

Nurmohamed N, Dallinga-Thie G, Stroes E . Targeting apoC-III and ANGPTL3 in the treatment of hypertriglyceridemia. Expert Rev Cardiovasc Ther. 2020; 18(6):355-361. DOI: 10.1080/14779072.2020.1768848. View

3.

Ginsberg H, Packard C, Chapman M, Boren J, Aguilar-Salinas C, Averna M . Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies-a consensus statement from the European Atherosclerosis Society. Eur Heart J. 2021; 42(47):4791-4806. PMC: 8670783. DOI: 10.1093/eurheartj/ehab551. View

4.

Chait A, Ginsberg H, Vaisar T, Heinecke J, Goldberg I, Bornfeldt K . Remnants of the Triglyceride-Rich Lipoproteins, Diabetes, and Cardiovascular Disease. Diabetes. 2020; 69(4):508-516. PMC: 7085249. DOI: 10.2337/dbi19-0007. View

5.

Brunner F, Waldeyer C, Ojeda F, Salomaa V, Kee F, Sans S . Application of non-HDL cholesterol for population-based cardiovascular risk stratification: results from the Multinational Cardiovascular Risk Consortium. Lancet. 2019; 394(10215):2173-2183. PMC: 6913519. DOI: 10.1016/S0140-6736(19)32519-X. View

6.

Packard C, Demant T, Stewart J, Bedford D, Caslake M, Schwertfeger G . Apolipoprotein B metabolism and the distribution of VLDL and LDL subfractions. J Lipid Res. 2000; 41(2):305-18. View

7.

Ference B, Ginsberg H, Graham I, Ray K, Packard C, Bruckert E . Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017; 38(32):2459-2472. PMC: 5837225. DOI: 10.1093/eurheartj/ehx144. View

8.

Raposeiras-Roubin S, Rossello X, Oliva B, Fernandez-Friera L, Mendiguren J, Andres V . Triglycerides and Residual Atherosclerotic Risk. J Am Coll Cardiol. 2021; 77(24):3031-3041. PMC: 8215641. DOI: 10.1016/j.jacc.2021.04.059. View

9.

Delatour V, Clouet-Foraison N, Gaie-Levrel F, Marcovina S, Hoofnagle A, Kuklenyik Z . Comparability of Lipoprotein Particle Number Concentrations Across ES-DMA, NMR, LC-MS/MS, Immunonephelometry, and VAP: In Search of a Candidate Reference Measurement Procedure for apoB and non-HDL-P Standardization. Clin Chem. 2018; 64(10):1485-1495. DOI: 10.1373/clinchem.2018.288746. View

10.

Langlois M, Sniderman A . Non-HDL Cholesterol or apoB: Which to Prefer as a Target for the Prevention of Atherosclerotic Cardiovascular Disease?. Curr Cardiol Rep. 2020; 22(8):67. DOI: 10.1007/s11886-020-01323-z. View

11.

Balling M, Langsted A, Afzal S, Varbo A, Davey Smith G, Nordestgaard B . Reply to: "Methodological issues regarding: "A third of nonfasting plasma cholesterol is in remnant lipoproteins: Lipoprotein subclass profiling in 9293 individuals"". Atherosclerosis. 2020; 302:57-58. DOI: 10.1016/j.atherosclerosis.2020.03.027. View

12.

Boren J, Chapman M, Krauss R, Packard C, Bentzon J, Binder C . Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2020; 41(24):2313-2330. PMC: 7308544. DOI: 10.1093/eurheartj/ehz962. View

13.

Palmer M, Barter P, Lundman P, Nicholls S, Toth P, Karlson B . Comparing a novel equation for calculating low-density lipoprotein cholesterol with the Friedewald equation: A VOYAGER analysis. Clin Biochem. 2018; 64:24-29. DOI: 10.1016/j.clinbiochem.2018.10.011. View

14.

Tsimikas S . In Search of Patients With Elevated Lp(a): Seek and Ye Shall Find. J Am Coll Cardiol. 2019; 73(9):1040-1042. DOI: 10.1016/j.jacc.2018.12.036. View

15.

Sampson M, Wolska A, Warnick R, Lucero D, Remaley A . A New Equation Based on the Standard Lipid Panel for Calculating Small Dense Low-Density Lipoprotein-Cholesterol and Its Use as a Risk-Enhancer Test. Clin Chem. 2021; 67(7):987-997. PMC: 8260186. DOI: 10.1093/clinchem/hvab048. View

16.

Chapman M, Ginsberg H, Amarenco P, Andreotti F, Boren J, Catapano A . Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. Eur Heart J. 2011; 32(11):1345-61. PMC: 3105250. DOI: 10.1093/eurheartj/ehr112. View

17.

Sniderman A . ApoB vs non-HDL-C vs LDL-C as Markers of Cardiovascular Disease. Clin Chem. 2021; 67(11):1440-1442. DOI: 10.1093/clinchem/hvab140. View

18.

Fujihara Y, Nakamura T, Horikoshi T, Obata J, Fujioka D, Watanabe Y . Remnant Lipoproteins Are Residual Risk Factor for Future Cardiovascular Events in Patients With Stable Coronary Artery Disease and On-Statin Low-Density Lipoprotein Cholesterol Levels <70 mg/dL. Circ J. 2019; 83(6):1302-1308. DOI: 10.1253/circj.CJ-19-0047. View

19.

Quispe R, Martin S, Michos E, Lamba I, Blumenthal R, Saeed A . Remnant cholesterol predicts cardiovascular disease beyond LDL and ApoB: a primary prevention study. Eur Heart J. 2021; 42(42):4324-4332. PMC: 8572557. DOI: 10.1093/eurheartj/ehab432. View

20.

Giugliano R, Pedersen T, Park J, De Ferrari G, Gaciong Z, Ceska R . Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial. Lancet. 2017; 390(10106):1962-1971. DOI: 10.1016/S0140-6736(17)32290-0. View